Effects of fluconazole on<i>Candida glabrata</i>biofilms and its relationship with ABC transporter gene expression

Fonseca, Elza; Silva, Sónia; Rodrigues, Célia Fortuna; Alves, Carlos; Azeredo, Joana; Henriques, Mariana

doi:10.1080/08927014.2014.886108

Cited by 54 publications

(60 citation statements)

References 30 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the clinical perspective, the most important characteristic of Candida species is their ability to form biofilms and their role in the increased tolerance to conventional antifungal therapy, since they are much more resistant to antifungal agents than planktonic cells (Donlan and Costerton, 2002;Fonseca et al, 2014;Galán-Ladero et al, 2013;Shanmughapriya et al, 2014;Silva et al, 2012). As expected, all strains were able to form biofilms and exhibited resistance to AMB but in a strain-dependent manner (Table 1).…”

Section: Discussionsupporting

confidence: 49%

“…In fact, some studies reported that C. tropicalis planktonic cells were susceptible to AMB, although their biofilms exhibited resistance, normally due to the synthesis of large amounts of matrix (Al-Fattani and Douglas, 2006;Bizerra et al, 2008;Kothavade et al, 2010;Negri et al, 2012;Silva et al, 2009). This fact was also described by other authors for Candida albicans and Candida glabrata biofilms (Fonseca et al, 2014;Kumamoto, 2002;Silva et al, 2012). As it is well known, mature biofilms are in cells organized into structured communities embedded within an ECM Silva et al, 2009Silva et al, , 2011Silva et al, , 2012.…”

Section: Discussionmentioning

confidence: 79%

See 1 more Smart Citation

Candida tropicalis biofilm's matrix—involvement on its resistance to amphotericin B

Fernandes

Silva

Henriques

2015

Diagnostic Microbiology and Infectious Disease

Self Cite

View full text Add to dashboard Cite

Candida tropicalis has emerged as one of the most prevalent fungal pathogens, and its ability to form biofilms has been considered one of the most important virulence factors, since they represent high tolerance to antifungal agents. However, the mechanisms of biofilm resistance to antifungal agents remain poorly understood. Thus, the main goal of this study was to infer about the ability of amphotericin B (AMB) to control and combat C. tropicalis biofilms. Additionally, it was also intended to determine the influence of matrix components in biofilm resistance. AMB was unable to totally prevent biofilm formation and to eradicate C. tropicalis preformed biofilms. Moreover, AMB led to a significant increase of the biofilm production due to an augment of the total protein and carbohydrate contents of the matrix. The C. tropicalis biofilm matrix assumes an important role on its resistance to AMB.

show abstract

Section: Discussionsupporting

confidence: 49%

Section: Discussionmentioning

confidence: 79%

Candida tropicalis biofilm's matrix—involvement on its resistance to amphotericin B

Fernandes

Silva

Henriques

2015

Diagnostic Microbiology and Infectious Disease

Self Cite

View full text Add to dashboard Cite

show abstract

“…The efflux of drugs mediated by efflux pumps is an important mechanism of antifungal resistance employed by Candida spp (37, 56, 57). From six distinct drug efflux transporters produced by the analyzed organisms, two of them (Cdr1 and orf19.4780) were more abundant in the fluconazole-resistant C. auris strain (MMC1) than in the other strains.…”

Section: Discussionmentioning

confidence: 99%

Candida auris: multi-omics signature of an emerging and multidrug-resistant pathogen

Zamith-Miranda

Heyman

Cleare

et al. 2019

Preprint

View full text Add to dashboard Cite

Candida auris is a recently described pathogenic fungus that is causing invasive 24 outbreaks on all continents. The fungus is of high concern given the numbers of multidrug-25 resistant strains that have been isolated in distinct sites across the globe. The fact that its 26 diagnosis is still problematic suggests that the spreading of the pathogen remains 27 underestimated. Notably, the molecular mechanisms of virulence and antifungal resistance 28 employed by this new species are largely unknown. In the present work, we compared two 29 clinical isolates of C. auris with distinct drug susceptibility profiles and a Candida albicans 30 reference strain using a multi-omics approach. Our results show that, despite the distinct 31 drug-resistance profile, both C. auris strains appear to be very similar, albeit with a few 32 notable differences. However, when compared to C. albicans both C. auris strains have 33 major differences regarding their carbon utilization and downstream lipid and protein 34 content, suggesting a multi-factorial mechanism of drug resistance. The molecular profile 35 displayed by C. auris helps to explain the antifungal resistance and virulence phenotypes of 36 this new emerging pathogen. 37Importance: Candida auris was firstly described in Japan in 2009 and has now been the 38 cause of significant outbreaks across the globe. The high number of isolates that are 39 resistant to one or more antifungals, as well as the high mortality rates from patients with 40 bloodstream infections, has caught the attention of the medical mycology, infectious 41 disease and public health communities to this pathogenic fungus. In the current work, we 42 performed a broad multi-omics approach on two clinical isolates isolated in New York, the 43 most affected area in the USA and found that the omic profile of C. auris differs 44 3 significantly from C. albicans. Besides our insights into C. auris carbon utilization and 45 lipid and protein content, we believe that the availability of these data will enhance our 46 ability to combat this rapidly emerging pathogenic yeast. 48Candida auris is an emerging pathogenic fungus that was firstly described in 2009 after 49 being isolated from the ear discharge of a patient in Tokyo, Japan (1). After the new species 50 identification, a study in South Korea reported a misidentified C. auris strain isolated in 51 1996, which then became the first known case of human C. auris infection (2). Despite the 52 fact that bloodstream infections are the main cause of mortality among Candida spp 53 infections, C. auris strains have been isolated from various sites such as respiratory tract, 54 bones, and central nervous system (3) as well as on a variety of abiotic surfaces (4), which 55 suggests a metabolic plasticity to survive in distinct environments. The reports of C. auris 56 outbreaks in all continents suggest that this pathogen is spreading rapidly across the globe 57 and many of the isolated strains are resistant to at least one class of antifungals, or even 58 multidrug-re...

show abstract

“…35,38,110 This is due to increased transporter genes, 111 increased expression of efflux pumps 112 and the propensity for biofilm formation. 113 Further, C. glabrata exists in a haploid state and hence is more prone to mutations. 114 Indeed, some features of resistant C. glabrata may allow for increased virulence.…”

mentioning

confidence: 99%

Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014

Chen

Sorrell

Chang

et al. 2014

Internal Medicine Journal

View full text Add to dashboard Cite

Pathogenic yeast forms are commonly associated with invasive fungal disease in the immunocompromised host, including patients with haematological malignancies and patients of haemopoietic stem cell transplants. Yeasts include the Candida spp., Cryptococcus spp., Pneumocystis jirovecii and some lesser-known pathogens. Candida species remain the most common cause of invasive yeast infections (and the most common human pathogenic fungi). These guidelines present evidence-based recommendations for the antifungal management of established, invasive yeast infections in adult and paediatric patients in the haematology/oncology setting. Consideration is also given to the critically ill patient in intensive care units, including the neonatal intensive care unit. Evidence for 'preemptive' or 'diagnostic-driven antifungal therapy' is also discussed. For the purposes of this paper, invasive yeast diseases are categorised under the headings of invasive candidiasis, cryptococcosis and uncommon yeast infections. Specific recommendations for the management of Pneumocystis jirovecii are presented in an accompanying article (see consensus guidelines by Cooley et al. appearing elsewhere in this supplement).

show abstract

Effects of fluconazole onCandida glabratabiofilms and its relationship with ABC transporter gene expression

Cited by 54 publications

References 30 publications

Candida tropicalis biofilm's matrix—involvement on its resistance to amphotericin B

Candida tropicalis biofilm's matrix—involvement on its resistance to amphotericin B

Candida auris: multi-omics signature of an emerging and multidrug-resistant pathogen

Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014

Contact Info

Product

Resources

About